thioacetazone and isatin-beta-thiosemicarbazone

thioacetazone has been researched along with isatin-beta-thiosemicarbazone* in 1 studies

Other Studies

1 other study(ies) available for thioacetazone and isatin-beta-thiosemicarbazone

ArticleYear
Synthesis, activity, and pharmacophore development for isatin-beta-thiosemicarbazones with selective activity toward multidrug-resistant cells.
    Journal of medicinal chemistry, 2009, May-28, Volume: 52, Issue:10

    We have recently identified a new class of compounds that selectively kill cells that express P-glycoprotein (P-gp, MDR1), the ATPase efflux pump that confers multidrug resistance on cancer cells. Several isatin-beta-thiosemicarbazones from our initial study have been validated and a range of analogues synthesized and tested. A number demonstrated improved MDR1-selective activity over the lead, NSC73306 (1). Pharmacophores for cytotoxicity and MDR1 selectivity were generated to delineate the structural features required for activity. The MDR1-selective pharmacophore highlights the importance of aromatic/hydrophobic features at the N4 position of the thiosemicarbazone and the reliance on the isatin moiety as key bioisosteric contributors. Additionally, a quantitative structure-activity relationship (QSAR) model that yielded a cross-validated correlation coefficient of 0.85 effectively predicts the cytotoxicity of untested thiosemicarbazones. Together, the models serve as effective approaches for predicting structures with MDR1-selective activity and aid in directing the search for the mechanism of action of 1.

    Topics: ATP Binding Cassette Transporter, Subfamily B, Member 1; Cell Death; Cytotoxins; Drug Resistance, Multiple; Enzyme Inhibitors; HeLa Cells; Humans; Hydrophobic and Hydrophilic Interactions; Indoles; Isatin; Quantitative Structure-Activity Relationship; Substrate Specificity

2009